| Register
| Log out
Submit An Article

FDA

Latest Articles

  • HeraMED to rollout telehealth maternity care in the lucrative U.S market

    HeraMED to rollout telehealth maternity care in the lucrative U.S market

    Prior to COVID-19 bringing attention to the value of telehealth, HeraMED (ASX: HMD) has been building digital infrastructure to revolutionise the maternal healthcare market with their screening and remote midwife platform which is preparing to now enter the lucrative U.S market.  The expansion into the world’s most lucrative healthcare market, valued at USD $111 billion

    Read More
    Public
  • Retired NFL players endorse Zilosul, Paradigm’s osteoarthritis drug trials

    Retired NFL players endorse Zilosul, Paradigm’s osteoarthritis drug trials

    Professional athletes may soon have a new treatment for knee osteoarthritis after Paradigm Biopharmaceuticals (ASX: PAR) received glowing endorsements from two former NFL players undergoing the current round of Zilosul® treatment trials.  The trials of Zilosul® have been conducted on ten patients suffering from varying degrees of knee osteoarthritis under the Food and Drug Administration’s

    Read More
    Public
  • FDA relaxes clinical trial guidelines, opens U.S opportunity to Visioneering

    FDA relaxes clinical trial guidelines, opens U.S opportunity to Visioneering

    Medtech developer Visioneering Technologies (ASX: VTI) may soon have its NaturalVue Multifocal (NVMF) contact lenses re-classified by the FDA which has just approved the first contact lenses which slow the progression of nearsightedness.  The FDA approval was given to CooperVision’s MiSight® 1 day contact lens which slows the progression of myopia specifically in children. The

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.